Earlier this week, Swiss pharma-giant Roche announced that Regeneron's investigational antibody cocktail - casirivimab and imdevimab - reduced risk of symptomatic Covid-19 infections by 81%. As per the agreement with Regeneron, Roche will manufacture and market the antibody cocktail outside of the..
Earlier this week, Swiss pharma-giant Roche announced that Regeneron's investigational antibody cocktail - casirivimab and imdevimab - reduced risk of symptomatic Covid-19 infections by 81%. As per the agreement with Regeneron, Roche will manufacture and market the antibody cocktail outside of the..
Share this Article
Recommended